Anothersimilar example was the NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease (PONTIAC) trial [56] which randomized diabetic patients with a NT-proBNP cut off of >125 pg/mL who were free of cardiac disease intoeither a control group or an intensified treatment group with renin-angiotensinsystem antagonists and beta blockers. Here, REN is linked to heart disorder.